Fig. 4From: Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibodyImmune cell subsets of a potentially biologic relevance following different doses of avelumab. Graphs display frequency as a percentage of PBMC for patients treated with 1 or 3Â mg/kg (left panels, triangle), 10Â mg/kg (middle panels, circle), and 20Â mg/kg (right panels, square) of avelumabBack to article page